Cambridge Cognition’s (COG) Corporate Rating Reaffirmed at FinnCap

FinnCap reissued their corporate rating on shares of Cambridge Cognition (LON:COG) in a research note issued to investors on Tuesday, ThisIsMoney.Co.Uk reports.

Shares of LON COG opened at GBX 44 ($0.54) on Tuesday. Cambridge Cognition has a 52 week low of GBX 16.50 ($0.20) and a 52 week high of GBX 72.38 ($0.89). The firm has a market cap of $11.85 million and a P/E ratio of -3.06. The business’s 50 day moving average price is GBX 28.58 and its 200 day moving average price is GBX 26.03.

Cambridge Cognition (LON:COG) last announced its quarterly earnings results on Tuesday, May 5th. The company reported GBX (12.40) (($0.15)) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of GBX (10.60) (($0.13)) by GBX (1.80) (($0.02)).

Cambridge Cognition Company Profile

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health products. The company offers CANTAB Recruit, an online patient recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from phases I-IV or a cognitive testing software that enhances the chances of success and minimizing the risk of failure in neuroscience research; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication.

See Also: 12b-1 Fees

Receive News & Ratings for Cambridge Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambridge Cognition and related companies with MarketBeat.com's FREE daily email newsletter.